Multiple Endocrine Neoplasia Type 2B: Diagnosis & Treatment

Multiple endocrine neoplasia type 2B (MEN 2B), also known as MEN IIB or Sipple syndrome, is a rare autosomal dominant genetic syndrome characterized by aggressive medullary thyroid carcinoma (MTC), pheochromocytoma, mucosal neuromas, gastrointestinal ganglioneuromatosis, and a distinctive marfanoid body habitus. It affects approximately 1 in 1 million individuals and is caused by specific germline mutations in the RET proto-oncogene, most commonly M918T in the tyrosine kinase domain.

What is the cause of multiple endocrine neoplasia type 2B?

MEN 2B results from activating germline mutations in the RET proto-oncogene located on chromosome 10q11.2. Over 95% of cases involve the M918T missense mutation (exon 16), leading to constitutive activation of the RET receptor tyrosine kinase, which promotes uncontrolled cell proliferation in neural crest-derived tissues such as C-cells of the thyroid and adrenal medulla.

Unlike MEN 2A, MEN 2B mutations are de novo in about 50% of cases, meaning they arise spontaneously without family history, often leading to delayed diagnosis. Penetrance for MTC is nearly 100%, with tumours developing in infancy.

• Genetic mechanism: The RET mutation causes ligand-independent dimerization and autophosphorylation, triggering downstream signalling pathways like MAPK/ERK that drive tumorigenesis.
• Inheritance: Autosomal dominant with high penetrance; genetic testing identifies at-risk family members.

Who gets multiple endocrine neoplasia type 2B?

MEN 2B typically presents in infancy or early childhood, with nearly all patients developing MTC by age 5 years. It has equal sex distribution and no ethnic predisposition. De novo cases often evade early detection due to lack of family history.

What are the clinical features of multiple endocrine neoplasia type 2B?

MEN 2B exhibits a classic triad of MTC, mucosal neuromas, and marfanoid habitus, with additional mesenchymal abnormalities. Mucosal neuromas often appear first, prompting diagnosis.

Marfanoid habitus

Tall, thin stature with long limbs, arachnodactyly, pectus excavatum/carinatum, scoliosis, and high-arched palate, resembling Marfan syndrome but without lens dislocation or aortic dilation.

Mucosal neuromas

Pathognomonic multiple submucosal neuromas present as painless, flesh-coloured papules/plaques on lips (everted, thickened), tongue, oral mucosa, eyelids, conjunctiva, and corneal nerves (thickened, tortuous). They are histologically benign neural tumours.

• Lips: Hypertrophied, nodular, ‘blubbery’ appearance from birth.
• Tongue: Multiple nodules impairing speech/swallowing.
• Eyes: Eyelid neuromas, prominent corneal nerves causing photophobia.

Medullary thyroid carcinoma

Aggressive MTC arises from C-cell hyperplasia, metastasizing early to cervical nodes, lungs, liver. Presents as rapidly enlarging anterior neck mass, hoarse voice, dysphagia. Elevated calcitonin/CEA confirms.

Pheochromocytoma

Bilateral adrenal medullary tumours in 50%, causing paroxysmal hypertension, headaches, palpitations, sweating. Often asymptomatic until advanced.

Gastrointestinal ganglioneuromatosis

Diffuse intestinal neural proliferation causing megacolon, constipation, diarrhoea, pseudo-obstruction, or malabsorption.

Other features

• Myopathy: Proximal muscle weakness.
• Facial: Coarse features, thick lips.
• Skeletal: Joint laxity, pes cavus.

Diagnosis of multiple endocrine neoplasia type 2B

Diagnosis combines clinical recognition, biochemical testing, imaging, and RET genetic testing. Early identification prevents MTC metastasis.

Suspected clinical diagnosis

Index of suspicion in infants/children with mucosal neuromas ± marfanoid habitus ± neck mass.

Biochemical testing

• Serum calcitonin (stimulated if basal normal): Elevated in MTC/CCH.
• Serum CEA.
• Plasma/urinary metanephrines/catecholamines for pheochromocytoma screening.
• Calcium/PTH (rare parathyroid disease).

Imaging

• Neck ultrasound ± CT/MRI for MTC/nodes.
• Abdominal MRI/CT for pheochromocytoma.
• Chest CT/PET for metastatic MTC (calcitonin >400 pg/mL).

Genetic confirmation

RET sequencing identifies M918T or other MEN 2B-specific mutations. Counsel families; test at-risk relatives.

What is the differential diagnosis for multiple endocrine neoplasia type 2B?

• MEN 2A: Similar MTC/pheochromocytoma but lacks neuromas/marfans; has parathyroid hyperplasia.
• Familial MTC: Isolated MTC without extrathyroid features.
• Marfan syndrome: Aortic dilation, ectopia lentis absent in MEN 2B.
• Von Recklinghausen neurofibromatosis: Café-au-lait spots, plexiform neurofibromas.
• Mucosal neuroma syndrome: Isolated neuromas without endocrine tumours.

What is the treatment for multiple endocrine neoplasia type 2B?

Prophylactic thyroidectomy

Total thyroidectomy with central neck dissection recommended before age 1 year in genetically confirmed cases to prevent MTC. Lifelong levothyroxine replacement required.

Therapeutic surgery for MTC

Compartment-oriented neck dissection (levels II-VI) for nodal metastases. External beam radiotherapy for unresectable disease.

Pheochromocytoma management

Cortical-sparing adrenalectomy (bilateral if needed) after alpha-blockade. Annual screening post-op.

Symptomatic care

Neuromas: Observation or cosmetic excision. GI symptoms: Laxatives, prokinetics.

Targeted therapy

Vandetanib, cabozantinib for advanced MTC (RET/MET/VEGF inhibitors).

Complications of multiple endocrine neoplasia type 2B

• MTC metastasis (mortality >50% if diagnosed late).
• Pheochromocytoma crisis.
• Megacolon/perforation.
• Hypothyroidism post-thyroidectomy.
• Adrenal insufficiency.

Prevention and prognosis of multiple endocrine neoplasia type 2B

Prevention: Prenatal/early postnatal RET testing in at-risk families enables prophylactic thyroidectomy, achieving >95% MTC cure rate.

Prognosis: Excellent with early intervention (5-year survival >90%); poor if metastatic MTC (median survival 2-3 years).

Guidelines for multiple endocrine neoplasia type 2B

• ATA: Prophylactic thyroidectomy by 1 year; annual calcitonin/CEA/BP screening.
• Genetic counselling mandatory.

Related topics

• Multiple endocrine neoplasia type 2A
• Medullary thyroid carcinoma
• Pheochromocytoma
• Marfan syndrome

Frequently asked questions about multiple endocrine neoplasia type 2B

What is MEN 2B?

MEN 2B is a rare genetic syndrome caused by RET mutations, featuring early aggressive MTC, mucosal neuromas, pheochromocytoma, and marfanoid habitus.

How is MEN 2B diagnosed?

By clinical features (neuromas, marfanoid), elevated calcitonin, imaging, and RET genetic testing.

When should thyroidectomy be performed in MEN 2B?

Prophylactically before age 1 year in confirmed cases to prevent MTC.

Is MEN 2B hereditary?

Yes, autosomal dominant; 50% de novo. Test family members.

What is the prognosis for MEN 2B?

Excellent with early thyroidectomy; poor if metastatic MTC develops.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb